Cytokinetics
CYTK
127 hedge funds and large institutions have $266M invested in Cytokinetics in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.12% less ownership
Funds ownership: 71.59% → 68.48% (-3.1%)
5% less funds holding
Funds holding: 134 → 127 (-7)
12% less call options, than puts
Call options by funds: $973K | Put options by funds: $1.1M
12% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 42
15% less capital invested
Capital invested by funds: $315M → $266M (-$48.2M)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.02M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$704K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$676K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$651K |
| 5 |
Millennium Management
New York
|
+$647K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.48M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.04M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.82M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.71M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.28M |
CYTK Hedge Fund Activity: Q1 2018 in Review
127 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2018, worth a combined $266M — down 15% from $315M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CYTK and 18 opened new positions — a net loss of 4 holders — while 42 trimmed existing stakes and 37 added.
The largest buyer was Deutsche Bank, adding an estimated $1.02M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.48M sold.
- 127 institutional investors held Cytokinetics (CYTK) as of Q1 2018, down from 134 in Q4 2017.
- Funds reported $266M of Cytokinetics stock for Q1 2018, down 15% quarter-over-quarter.
- 18 funds opened new Cytokinetics positions in Q1 2018 and 22 closed out, a net change of -4 holders.
- The largest Cytokinetics buyer in Q1 2018 was Deutsche Bank, an estimated $1.02M added.
- The largest Cytokinetics seller in Q1 2018 was T. Rowe Price Associates, an estimated $3.48M sold.
Based on aggregated 13F filings for Q1 2018.